Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Mark E Bernard"'
Autor:
Kimmen eQuan, Karen Mann Xu, Ron eLalonde, Zachary D Horne, Mark E Bernard, Chuck eMcCoy, David Anthony Clump, Steven eBurton, Dwight E Heron
Publikováno v:
Frontiers in Oncology, Vol 5 (2015)
Purpose: The aim is to provide a practical approach to the planning technique and evaluation of plan quality for the multi-lesion, single-isocenter stereotactic ablative radiotherapy (SABR) of the lung. Methods and Materials: Eleven patients with 2 o
Externí odkaz:
https://doaj.org/article/ea5a9521e37a46209f6c7b32bbae71fe
Autor:
Mark E. Bernard, MD, Philip A. Sutera, BS, Nicholas A. Iarrobino, BS, Kimmen Quan, MD, Steven A. Burton, MD, Nathan Bahary, MD, Melissa Hogg, MD, Amer Zureikat, MD, Dwight E. Heron, MD, MBA, FACRO, FACR
Publikováno v:
Advances in Radiation Oncology, Vol 4, Iss 2, Pp 294-301 (2019)
Purpose: Patients with close or positive margins after surgery for pancreatic carcinoma are at a high risk for recurrence. Stereotactic body radiation therapy (SBRT) allows for safe dose escalation with great conformity and short duration of treatmen
Externí odkaz:
https://doaj.org/article/45f0b4340837444d9346959b8edd322d
Autor:
Charles A. Kunos, Rodney Howells, Aman Chauhan, Zin W. Myint, Mark E. Bernard, Riham El Khouli, Jacek Capala
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Radiopharmaceuticals are reemerging as attractive anticancer agents, but there are no universally adopted guidelines or standardized procedures for evaluating agent validity before early-phase trial implementation. To validate a radiopharmaceutical,
Externí odkaz:
https://doaj.org/article/0a22045efcf944778aceb5256be6b844
Autor:
Jingwei Duan, Mark E. Bernard, James R. Castle, Xue Feng, Chi Wang, Mark C. Kenamond, Quan Chen
Publikováno v:
Medical Physics. 50:2715-2732
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5cf693edf9bf0a779dd77bf67ca85528
https://doi.org/10.1002/mp.16299
https://doi.org/10.1002/mp.16299
Autor:
Shearwood McClelland, III, MD, Tasneem Kaleem, MD, Mark E. Bernard, MD, Hiba Z. Ahmed, MD, Terence T. Sio, MD, MS, Robert C. Miller, MD, MBA
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 4, Pp 471-477 (2018)
Purpose: Compared with the rest of the United States, the population of Appalachia has lower education levels, higher rates of poverty, and limited access to health care. The presence of disparities in radiation therapy (RT) access for Appalachian pa
Externí odkaz:
https://doaj.org/article/53f9e7d419904eb3a5b4ec1e5f79683e
Publikováno v:
Journal of Applied Clinical Medical Physics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8867d31da56e295e9f19fbb356b1513
https://doi.org/10.1002/acm2.14047
https://doi.org/10.1002/acm2.14047
Publikováno v:
Medical Dosimetry.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::158ecd10f7f91a5569e3de97bd494555
https://doi.org/10.1016/j.meddos.2023.03.005
https://doi.org/10.1016/j.meddos.2023.03.005
Publikováno v:
Medical Dosimetry. 47:20-25
To evaluate the plan quality, treatment delivery efficiency, and accuracy of single-isocenter/multi-target (SIMT) volumetric modulated arc therapy (VMAT) of double-vertebral segments stereotactic body radiation therapy (SBRT) on Halcyon ring delivery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa280c3cf8f416031649e5351ff6fad
https://doi.org/10.1016/j.meddos.2021.07.001
https://doi.org/10.1016/j.meddos.2021.07.001
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Introduction: Pancreatic ductal adenocarcinoma (PDAC) commonly presents later in life with a median age at diagnosis of 70 years. Unfortunately, elderly patients are significantly underrepresented in clinical trials. Stereotactic body radiation thera
Externí odkaz:
https://doaj.org/article/0986fc30a42c470983dad50bb364b44e
Autor:
Philip Sutera, Mark E. Bernard, Hong Wang, Nathan Bahary, Steven Burton, Herbert Zeh, Dwight E. Heron
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
IntroductionPancreatic adenocarcinoma is an aggressive malignancy that has consistently demonstrated poor outcomes despite aggressive treatments. Despite multimodal treatment, local disease progression and local recurrence are common. Management of r
Externí odkaz:
https://doaj.org/article/3d66dd1c26974e8f8d616484adb6b095